Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Autologous natural killer cells,Cetuximab,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of this agreement, NKMax will be the study sponsor, and Merck KGaA, Darmstadt, Germany will supply cetuximab for a Phase I/IIa clinical trial in NSCLC patients for weekly dosing with 250 mg/m2 cetuximab administered by intravenous injecti...
Brand Name : SNK01
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : Autologous natural killer cells,Cetuximab,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Merck Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AFM24,SNK01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Affimed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumors.
Brand Name : AFM24
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : AFM24,SNK01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Affimed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : FDA has granted permission to amend its existing Phase I trial to add a new cohort of up to 18 patients to be treated with SNK01 in combination with either Pembrolizumab or Avelumab, two established checkpoint inhibitors.
Brand Name : SNK01
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 31, 2020
Lead Product(s) : SNK01,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company plans to initiate a Phase 1/2a open-label, multi-center trial (Study SNK01-102) to evaluate the safety and anti-tumor activity of its expanded autologous natural killer cells in combination with trastuzumab or cetuximab in third quarter of th...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 02, 2020
Lead Product(s) : SNK01,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SNK-01,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference
Details : The abstract is based on a randomized phase I/IIa study to evaluate the safety and efficacy of SNK-01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) plus Pembrolizumab in patients with stage IV non-small cell lung c...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 29, 2020
Lead Product(s) : SNK-01,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Autologous natural killer cells,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company to present three abstract titles related to SNK-01, an autologous NK cell adoptive immunotherapy for the upcoming 2020 American Society of Clinical Oncology (ASCO) annual meeting.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 30, 2020
Lead Product(s) : Autologous natural killer cells,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?